Page last updated: 2024-11-13
jnj-31020028
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 25134625 |
| CHEMBL ID | 1823342 |
| SCHEMBL ID | 1173864 |
| MeSH ID | M0543769 |
Synonyms (32)
| Synonym |
|---|
| jnj-31020028 , |
| CHEMBL1823342 , |
| bdbm50352371 |
| 1094873-14-9 |
| unii-73f8xed6yp |
| n-(4-(4-((n,n-diethylcarbamoyl)(phenyl)methyl)piperazin-1-yl)-3-fluorophenyl)-2-(pyridin-3-yl)benzamide |
| 73f8xed6yp , |
| 1-piperazineacetamide, n,n-diethyl-4-(2-fluoro-4-((2-(3-pyridinyl)benzoyl)amino)phenyl)-alpha-phenyl- |
| S6416 |
| 1-piperazineacetamide, n,n-diethyl-4-(2-fluoro-4-((2-(3-pyridinyl)benzoyl)amino)phenyl)-.alpha.-phenyl- |
| n-{4-[4-(diethylcarbamoyl-phenyl-methyl)-piperazin-1-yl]-3-fluoro-phenyl}-2-pyridin-3-yl-benzamide |
| (-)-n-{4-[4-(diethylcarbamoyl-phenyl-methyl)-piperazin-1-yl]-3-fluoro-phenyl}-2-pyridin-3-yl-benzamide |
| OVUNRYUVDVWTTE-UHFFFAOYSA-N , |
| SCHEMBL1173864 |
| CS-3499 |
| HY-14450 |
| jnj 31020028 |
| jnj31020028 |
| n-(4-(4-(2-(diethylamino)-2-oxo-1-phenylethyl)piperazin-1-yl)-3-fluorophenyl)-2-(pyridin-3-yl)benzamide |
| J-690028 |
| AKOS026750301 |
| EX-A712 |
| n-(4-{4-[(diethylcarbamoyl)(phenyl)methyl]piperazin-1-yl}-3-fluorophenyl)-2-(pyridin-3-yl)benzamide |
| n-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide |
| mfcd18782744 |
| n-[4-[4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl]-3-fluorophenyl]-2-pyridin-3-ylbenzamide |
| NCGC00390574-01 |
| F15275 |
| BCP14600 |
| EX-A3333 |
| Q27266173 |
| AS-56367 |
Research Excerpts
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (9)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 4.2534 | 0.0123 | 7.9835 | 43.2770 | AID1645841 |
| G | Vesicular stomatitis virus | Potency | 9.5221 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 18.9991 | 0.0010 | 8.3798 | 61.1304 | AID1645840 |
| Interferon beta | Homo sapiens (human) | Potency | 9.5221 | 0.0033 | 9.1582 | 39.8107 | AID1645842 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 9.5221 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 9.5221 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 9.5221 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Neuropeptide Y receptor type 2 | Homo sapiens (human) | IC50 (µMol) | 0.0060 | 0.0002 | 0.7480 | 4.4000 | AID1063861; AID616660 |
| Microsomal triglyceride transfer protein large subunit | Homo sapiens (human) | IC50 (µMol) | 0.7100 | 0.0000 | 0.7263 | 5.7500 | AID758788 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (68)
Molecular Functions (34)
Ceullar Components (30)
Bioassays (20)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1063837 | Cmax in rat at 10 mg/kg, sc | 2014 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2 | Ligands of the neuropeptide Y Y2 receptor. |
| AID1063844 | Selectivity ratio of NPYY4 receptor (unknown origin) to NPYY2 receptor (unknown origin) | 2014 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2 | Ligands of the neuropeptide Y Y2 receptor. |
| AID616660 | Displacement of [125I]PYY from human NPY Y2 receptor expressed endogenously in KAN-Ts cells by scintillation counting | 2011 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 21, Issue:18 | The discovery and synthesis of JNJ 31020028, a small molecule antagonist of the Neuropeptide Y Y₂ receptor. |
| AID1063839 | Oral bioavailability in rat at 10 mg/kg | 2014 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2 | Ligands of the neuropeptide Y Y2 receptor. |
| AID758787 | Metabolic stability in rat liver microsomes assessed as compound remaining after 15 mins | 2013 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14 | The discovery of potent selective NPY Y(2) antagonists. |
| AID1063861 | Displacement of [125I]-NPY from NPYY2 receptor (unknown origin) | 2014 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2 | Ligands of the neuropeptide Y Y2 receptor. |
| AID1063842 | Selectivity ratio of NPYY5 receptor (unknown origin) to NPYY2 receptor (unknown origin) | 2014 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2 | Ligands of the neuropeptide Y Y2 receptor. |
| AID1063840 | Bioavailability in rat at 10 mg/kg, sc | 2014 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2 | Ligands of the neuropeptide Y Y2 receptor. |
| AID1063841 | Antagonist activity at NPYY2 receptor (unknown origin) | 2014 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2 | Ligands of the neuropeptide Y Y2 receptor. |
| AID1063845 | In vivo occupancy of NPYY5 receptor in rat brain at 10 mg/kg, sc | 2014 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2 | Ligands of the neuropeptide Y Y2 receptor. |
| AID758788 | Inhibition of MTP (unknown origin) | 2013 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14 | The discovery of potent selective NPY Y(2) antagonists. |
| AID758789 | Metabolic stability in human liver microsomes assessed as compound remaining after 15 mins | 2013 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14 | The discovery of potent selective NPY Y(2) antagonists. |
| AID1063838 | Half life in rat at 10 mg/kg, sc | 2014 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2 | Ligands of the neuropeptide Y Y2 receptor. |
| AID1063836 | In vivo occupancy of NPYY5 receptor in sc dosed rat brain | 2014 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2 | Ligands of the neuropeptide Y Y2 receptor. |
| AID1063843 | Selectivity ratio of NPYY1 receptor (unknown origin) to NPYY2 receptor (unknown origin) | 2014 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2 | Ligands of the neuropeptide Y Y2 receptor. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (19)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 15 (78.95) | 24.3611 |
| 2020's | 4 (21.05) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 20.72
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.72) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (5.26%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 18 (94.74%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||